2型糖尿病周围神经病变与血清TAOC、MDA、SOD相关性研究

测定89例NDPN患者与33例DPN患者的TAOC及MDA,SOD水平,同时记录血压、身高、体重、血肌酐(Scr)、血尿酸(UA)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)、甘油三酯(TG)、总胆固醇(TC)、纤维蛋白原(FIB)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、计算体重指数(BMI)。采用肌电图测定神经传导速度(NCV)。结果非DPN组与DPN组比较BMI、收缩压(SBP)、舒张压(DBP)、FPG、TC、TG、HDL、LDL、Scr、UA、HbA1c、SOD无统计学差异(P>0.05),而年龄、病程、FIB、TAOC、MDA在两组间有统计学差异(P<0.05),通过多因素Logistic回归分析:MDA、年龄、病程进入回归方程(P<0.05)。结论年龄、病程、血清的MDA水平的增高,与糖尿病周围神经病变的发生相关。     

2型糖尿病周围神经病变危险因素分析

目的 探讨糖尿病周围神经病变(Dial-betic peripheral neuropathy,DPN)的相关临床危险因素.方法 对547例2型糖尿病住院患者进行双下肢肌电电生理检查,分为DPN组以及非DPN(NDPN)组.测定体质量指数、血压、血糖、胰岛素、C肽、糖化血红蛋白、血脂、尿白蛋白/肌酐比值(尿A/C)等指标.对各指标进行单因素分析,然后进行Logistic多元回归分析.结果 DPN组的病程、年龄、OGTT试验空腹及餐后血糖、甘油三酯、总胆固醇、低密度脂蛋白胆固醇、糖化血红蛋白、尿A/C水平高于NDPN组,而空腹以及OGTT2 h的胰岛素和C肽水平低于非NDPN组.多元回归分析显示:年龄、病程、OGTT试验空腹及2 h血糖、尿A/C与DPN呈正相关,而空腹以及OTGG试验2 h的胰岛素和C肽水平与DPN呈负相关.结论 年龄、病程、尿A/C、空腹以及OGTT试验2 h血糖、胰岛素、C肽是DPN的危险因素.     

新诊断老年2型糖尿病患者血清脂肪细胞型脂肪酸结合蛋白水平及意义

目的观察新诊断老年2型糖尿病(T2DM)患者血清脂肪细胞型脂肪酸结合蛋白(A-FABP)水平的变化及意义。方法通过比较72例新诊断T2DM患者与30例健康体检者(正常对照组)血糖、血脂、胰岛素抵抗指数(HOMA-IR)、胰岛β细胞功能指数(HOMA-β)及A-FABP等方面的差异,并分析A-FABP与血糖、血脂、HOMA-IR、HOMA-β的相关性。结果老年T2DM组体重指数(BMI)、空腹血糖(FPG)、餐后血糖(PPG)、糖化血红蛋白(Hb A1c)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、HOMA-IR和A-FABP显著高于正常对照组(P<0.05),而HOMA-β和高密度脂蛋白胆固醇(HDL-C)低于正常对照组(P<0.05),Pearson相关分析显示T2DM患者血清A-FABP与Hb A1c、PPG、TC、TG以及HOMA-IR呈正相关。结论老年T2DM患者血清A-FABP水平升高与胰岛素敏感性下降、糖脂代谢紊乱加重密切相关。     

高血压患者糖代谢异常的评价

该文探讨高血压患者的糖代谢情况及其高危因素分析。方法：对高血压患者562例进行口服葡萄糖耐量试验（OGTT），根据血糖分为正常葡萄糖耐量（NGT）、空腹血糖受损（IFG）、葡萄糖耐量减低（IGT）和糖尿病4组，分析各组的发病率，对各组的血脂（TG、TC、HDL、LDL）、体质量指数、HOMA-IR、8细胞功能（HOMA-β）、胰岛素敏感性指数（ISI）、     

2型糖尿病患者周围神经病变危险因素研究

选取T2DM患者共95例,进行神经传导速度（NCV）检测,分为有DPN组（阳性组）和NDPN组（阴性组）。同时检测年龄、病程、收缩压、空腹血糖（FPG）、空腹胰岛素（FIRI）、餐后2小时血糖（2hPG）及血脂各项指标,并计算胰岛素抵抗指数（HOMA—IR）。结果两组之间收缩压、甘油三酯（TG）、高密度脂蛋白（HDL）、（LDL）、2hPG、FIRI、HOMA—IR差异无统计学意义。阳性组年龄、病程、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL）、明显高于阴性组（P〈0．05）。结论年龄、病程、TC、LDL是DPN的危险因素。     

吡格列酮对糖耐量异常患者的干预作用

目的 观察吡格列酮对糖耐量异常患者的治疗效果.方法 用随机双盲法比较119例老年糖耐量异常患者在饮食加运动控制的基础上给予口服吡格列酮和安慰剂干预治疗,经治疗1年后,检测空腹血糖(FPG)及葡萄糖耐量试验(OGTT)后2 h血糖(2hPG),总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、胰岛素抵抗指数、空腹胰岛素(FINS)和OGTT后2 h胰岛素(PINS)水平的变化.结果 吡格列酮组与安慰剂组相比FPG、2 hPG、TC、TG、LDL、FINS及PINS均明显下降,HDL升高,吡格列酮组糖尿病的发病率为3.3%,低于安慰剂组的发病率(8.5%).结论 吡格列酮能够降低IGT人群糖尿病的发病率,在调节血脂、减轻胰岛素抵抗的同时,可使糖耐量异常明显改善.     

甘舒霖40R强化治疗对初诊2型糖尿病患者胰岛功能及胰岛素抵抗的影响

对32例初诊2型糖尿病患者进行每日2次甘舒霖40R胰岛素强化治疗12周,测定空腹血糖(FPG)、空腹胰岛素(FIns)及糖化血红蛋白(Hb A1c),计算稳态模型法β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)以及定量胰岛素敏感性指数(QUICKI)。结果治疗后,患者HOMA-β及QUICKI均升高(P 0. 001及P 0. 05); FIns,HOMA-IR,FPG,Hb A1c均下降(均P 0. 001)。结论:短期甘舒霖40R强化治疗能够改善初诊2型糖尿病患者胰岛β细胞功能,减轻IR,降糖效果确切。     

早发2型糖尿病血清尿酸的临床研究

对56例早发(DM)及52例(DGTT)及(HbAIC)均正常者(NGT)检测总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、(SUA)和肌酐(SCr),测量体质量指数(BMI)和腰臀比(WHR);用稳态模型胰岛素抵抗指数(HOMA-IR)评估胰岛素抵抗,胰岛β细胞功能指数(HOMA-β)评估岛素基础分泌,采用OGTT中空腹和30分钟胰岛素血糖差值的比值(△I30/△G30)评价胰岛素早期分泌.结果①DM和NGT组间SUA差异无统计学意义,HDL、HOMA-β、△I30/△G30显著低于NGT组,HOMA-IR、TG、BMI、WHR、OGTT2小时胰岛素显著高于NGT组;②在NGT组,调整年龄、BMI、血压、TG后,男性的尿酸水平仍高于女性;③在所有的个体中,逐步多元回归分析,发现Ser、BMI、性别、TG是影响血尿酸的独立因素.结论血尿酸水平在2型糖尿病发生的不同阶段无显著性变化,Scr、性别、BMI、TG是影响尿酸水平的独立因素.     

糖尿病性脑血管病易患因素分析

目的 探讨糖尿病性脑血管病的易患因素。方法 调查糖尿病患者100人，其中伴有脑血管病患者50人作为观察组，不伴有脑血管病者50人为对照组，对两组患者的空腹血糖（FBG）、空腹血浆胰岛素、糖化血红蛋白（HbA1c)，总胆固醇（TC），甘油三酯（TG),低密度脂蛋白胆固醇（LDL－C）、高密度脂蛋白胆固醇（HDL－C）及血压进行了测定分析。结果 观察组的FBG空腹血浆胰岛素TC、TG、LDL－C、血压明显高于对照组，观察组的HDL－C明显低于对照组。结论 高血糖、高血胰岛素水平、高血压、高血脂是糖尿病性脑血管病的易患因素。     

上海地区中国人血脂紊乱类型与胰岛素抵抗

目的：探讨上海地区中国人脂代谢紊乱的类型与胰岛素抵抗的关系。方法：830例年龄≥40岁（男300例,女530例）正常人和血脂紊乱者,后者分为7个亚组,包括单纯低高密度脂蛋白（HDL）组（亚组Ⅰ）、单纯高甘油三酯（TG）组（亚组Ⅱ）、单纯高胆固醇（TC）或高低密度脂蛋白（LDL）组（亚组Ⅲ）、低HDL合并高TG组（亚组Ⅳ）、低HDL合并高TC或高LDL组（亚组Ⅴ）、高TG合并高TC或高LDL组（亚组Ⅵ）、低HDL合并高TG及高TC或高LDL组（亚组Ⅶ）,用稳态模式评估法（HOMA）评价胰岛素抵抗（IR）。结果：校正年龄、性别、体重指数等因素后,伴有高TG的各血脂异常 亚组的胰岛素抵抗指数升高较为明显,总体脂、腹部脂肪对血脂紊乱的影响较为显著;体脂对胰岛素抵抗指数的影响部分是通过TG介导的,结论：TG升高可作为个体存在胰岛纱抵抗的指标。     

Metabolic characteristics of subjects with normal glucose tolerance and 1-h hyperglycaemia

Objective Nondiabetic subjects with a 1‐h plasma glucose ≥ 11·1 mmol/l during an oral glucose tolerance test (OGTT) drew our attention to their somewhat confusing status and relative frequency among Chinese patients. The aim of this study was to clarify the metabolic characteristics of these subjects. Design and patients A total of 2549 Chinese subjects were included in this study. Based on results of OGTT, these subjects were classified into three groups: normal glucose tolerance (NGT), impaired glucose regulation (IGR) and diabetes mellitus (DM). Then, according to the level of 1‐h plasma glucose, the NGT and IGR groups were subclassified, respectively, as: NGT without 1‐h hyperglycaemia (NGTN), NGT with hyperglycaemia at 1 h (NGT1H), IGR without 1‐h hyperglycaemia (IGRN), and IGR with hyperglycaemia at 1 h (IGR1H). Results After adjustments for age and gender, the insulinogenic index (IGI) of NGT1H and IGR1H was found to be lower than for those with NGTN and of IGRN, respectively (P < 0·05). No statistical differences, however, were found in oral glucose insulin sensitivity (OGIS) between either of the 1‐h hyperglycaemic groups or of the corresponding NGTN or IGRN groups. Homeostasis model assessment for β‐cell function (HOMA‐B) of NGT1H was lower than that of NGTN (P < 0·05), while IGRN and IGR1H showed no difference. No differences in homeostasis model assessment for insulin resistance (HOMA‐IR) were found among NGTN, NGT1H, IGRN and IGR1H groups. The levels of triglycerides (TG) were not significantly different among NGT1H, IGRN and IGR1H, while TG in these groups were significantly higher than in NGTN (P < 0·05). LDL‐C was significantly higher and HDL significantly lower in NGT1H than in all other groups (P < 0·05).The IGR group was also subclassified as: isolated impaired fasting glucose (IFG), isolated impaired glucose tolerance (IGT) and combined glucose intolerance (CGI). The IGI of the NGT1H group was similar to the IGI that of combined glucose intolerance group but lower than those of IFG and IGT (P < 0·05).The OGIS of the NGT1H group was the highest among all groups (P < 0·05). HOMA‐B of IGT and NGT1H were higher than that of IFG (P < 0·05). There was no difference among all groups in HOMA‐IR. Plasma lipid levels were not significantly different between NGT1H and any other group. Conclusions Chinese NGT subjects with a 1‐h plasma glucose ≥ 11·1 mmol/l are characterized by metabolic abnormalities, which may be caused by the impairment of early insulin release rather than aggravated insulin resistance.     

Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation

Background Both beta‐cell dysfunction and decreased insulin sensitivity are involved in the pathogenesis of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG), while their relative contribution in the progression to type 2 diabetes still remains controversial. The aim of the present study is to clarify this process in Chinese subjects by using cross‐sectional method. Methods 2975 Chinese subjects were classified into: normal glucose tolerance (NGT), impaired glucose regulations (IGR), and diabetes mellitus (DM) based on oral glucose tolerance test (OGTT). The IGR group was sub‐classified as isolated IFG, isolated IGT and combined glucose intolerance (CGI). The DM group was sub‐classified as normal fasting plasma glucose and 2‐hour hyperglycemia (N0D2), fasting hyperglycemia and normal 2‐hour plasma glucose (D0N2), and both fasting and 2‐hour hyperglycemia (D0D2). Results As far as insulinogenic index (IGI) was concerned, there was no difference between IFG and IGT in either gender, however, HOMA2‐B% (homeostasis model assessment for beta‐cell function) of IGT was higher than that of IFG and CGI in both male and female (P < 0.05). In the diabetic sub‐groups, IGI of N0D2 was higher than that of D0N2, and both deteriorated compared with those of IGT and IFG, respectively. HOMA2‐B% of N0D2 was still higher than that of D0N2 and D0D2. No significant difference was detected in OGIS and HOMA2‐S% (homeostasis model assessment for insulin sensitivity) between IFG and IGT, and this was the case between N0D2 and D0N2. OGIS and HOMA‐IR of IGR sub‐groups were not different from those of their diabetic counterparts. Conclusion Failure of beta‐cell function might be the main reason for both IGT and IFG developing into diabetes instead of aggravated insulin resistance. Copyright © 2008 John Wiley & Sons, Ltd.     

Glucose metabolism in non-diabetic patients with stable coronary artery disease.

BACKGROUND: Diabetes and other forms of impaired glucose metabolism (IGM) can be present in patients with coronary artery disease (CAD), despite normal fasting glycemia and no prior evidence of diabetes. Undiagnosed IGM can be associated with increased risk of cardiovascular events. OBJECTIVE: To assess the prevalence of IGM in patients with CAD and without diabetes and to identify its repercussions on their cardiovascular risk profile. METHODS: Consecutive patients with CAD documented by angiography, without prior history of diabetes and fasting glycemia < 126 mg/dL, were studied. An oral glucose tolerance test (OGTT) was performed to identify and classify IGM. The patients were divided into three groups: normal if fasting glycemia < 100 mg/dL and normal OGTT; prediabetes if fasting glycemia > or = 100 mg/dL and abnormal OGTT, with 2-h glycemia > or = 140 and < 200 mg/dL; and diabetes if 2-h glycemia > or = 200 mg/dL after OGTT. For assessment of the cardiovascular risk profile, various clinical, laboratorial (including lipid profile, fasting insulinemia 2 h after OGTT, insulin resistance index and A1c hemoglobin) and angiographic characteristics were analyzed. The differences between groups were determined. RESULTS: 54 patients were studied (mean age 65 +/- 9 years, 78 % male) and IGM was identified in 37 (69%), with prediabetes in 23 (43%) and diabetes in 14 (26%). Patients with IGM had more dyslipidemia, higher levels of fasting glycemia, triglycerides and urea and lower HDL cholesterol. Metabolic syndrome was diagnosed in 12% of patients in the normal group, 44% in the prediabetes group and 50% in the diabetes group (p = 0.047). CAD was more severe in the presence of IGM, being multivessel in 84% of these patients versus 59% in the normal group (p = 0.046). CONCLUSION: In patients with CAD without clinical suspicion of diabetes, a routine OGTT can identify a significant percentage with prediabetes and diabetes, which can have a negative impact on their cardiovascular risk profile.     

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.

The sulfonylurea gliclazide and the biguanide metformin have different mechanisms to reduce glycemia. We performed a randomized study to compare these two agents with respect to glycemic control and effects on lipid peroxidation markers in 36 adult patients with type 2 diabetes. Both agents significantly decreased glycosylated hemoglobin ([HbA1c] P < .05), fructosamine (P < .05), and the glucose-excursion curve during the oral glucose tolerance test ([OGTT] P < .01). With regard to the insulin curve during this test, no significant change was observed with metformin and a significant increase was measured with gliclazide (P < .05). Considering the small number of events, no significant difference was detected in the number of hypoglycemic episodes between the two agents. More upper-gastrointestinal (GI) symptoms were observed with metformin compared with gliclazide (P < .05). Even with no change in the standard lipid profile, both agents increased serum vitamin E (P < .01 for gliclazide and P < .05 for metformin) and decreased the level of lipid peroxidation markers in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles (P < .05). Despite different mechanisms of action, gliclazide and metformin demonstrated comparable levels of efficacy and complementary effects on lipid peroxidation markers.     

Ⅱ型糖尿病并高血压患者胰岛素和脂蛋白水平的关系

目的：通过测定非胰岛素依赖型糖尿病（NIDDM）并高血压患者血中胰岛素浓度以了解高胰岛素血症与高血压脂蛋白代谢异常的关系。方法：配对观察高血压及无高血压糖尿病（HP－NIDDM组及NP－NIDDM组）各35例，行口服葡萄糖耐量和胰岛素释放试验，并与30例正常人（对照组）进行比较，分别测空腹，30、60、120、180min血糖及胰岛素水平，计算出胰岛素曲线下面积，三组均测血浆甘油三酯（TG）、胆固醇（TC）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、载脂蛋白AI（apoAI），载脂蛋白B（apoB）及糖化血红蛋白（HbAic）。结果：HP－NIDDM组的体重指数（BMI）、TC、TG、LDL、apoB和HbAic高于对照组，HDL、apoAI低于对照组（均P＜0．05），TG、LDL、apoB和HbAic高于NP－NIDDM组，HDL、apoAI低于NP－NIDDM组（均P＜0．05），而BMI、TC及HbAic无统计学差异（均P＞0．05）；NP－NIDDM组的TC、TG、LDL和HbAic高于对照组，HDL低于对照组（均P＜0．05），余无统计学差异（均P＞0.05）。结论：HP－NIDDM患者存在胰岛素抵抗及高胰岛素血症与血脂apoAI、apoB关系密切。     

不同糖耐量者血清游离脂肪酸与胰岛素抵抗的关系

以口服糖耐量试验(OGTT)确定受试者为正常人,糖耐量低减(IGT)和2型糖尿病,并测定空腹和OGTT 2h的游离脂肪酸(FFA)、血糖和胰岛素浓度,计算胰岛素敏感指数(IAI)。2型糖尿病和IGT患者的空腹和OGTT 2 h FFA、血糖和胰岛素浓度均明显高于正常组(均P<0.05),IAI均明显低于正常对照组(均P<0.01)。空腹及OGTT 2 h FFA与IAI之间呈显著负相关(分别为r=-0.38,P<0.01和r=-0.32,P<0.05),体重指数与IAI呈显著负相关(r=-0.39,P<0.05)。上述结果提示脂毒性在2型糖尿病的发病机制中有重要作用。     

Relative utility of 1-h Oral Glucose Tolerance Test as a measure of abnormal glucose homeostasis

Background and aims

Impaired glucose tolerance based on 2-h glucose levels is more predictive of future cardiovascular disease and more sensitive in detecting earlier diabetes compared to impaired fasting glucose. However, the 1-h OGTT may be even more sensitive than the 2-h. We assessed the relative value of 1-h OGTT by exploring its relationship with adiposity and other measures of glucose homeostasis.

Methods and results

Ninety four overweight/obese individuals free of diabetes and major cardiovascular conditions were included in the analyses. We adjusted for age, gender, smoking status and physical activity. One-h OGTT showed similar partial correlations with fasting glucose and 2-h OGTT (r = 0.60 and 0.64 respectively). Fasting glucose, fasting insulin and HOMA correlated better with 1-h OGTT (r = 0.60, 0.47 and 0.52) than with 2-h OGTT (r = 0.50, 0.41, and 0.45). BMI and waist circumference also showed stronger correlation with 1-h (r = 0.31, 0.29), compared to 2-h OGTT (r = 0.16, 0.16) or fasting glucose (r = 0.23, 0.22). Metabolic syndrome was associated similarly with 1-h and 2-h OGTT.

Conclusions

The 1-h OGTT correlates well with both fasting glucose and 2-h OGTT and shows similar or higher associations with obesity measures. The 1-h OGTT has potential utility in epidemiologic studies.     

Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance

AIMS: To assess the efficacy and long-term effects of glipizide treatment on glucose and insulin metabolism in individuals with impaired glucose tolerance (IGT). METHODS: Thirty-seven first-degree relatives of patients with type 2 diabetes fulfilling WHO criteria for IGT were randomized to treatment with either glipizide 2.5 mg once daily or matching placebo for 6 months. A 75 g, 2-h oral (OGTT) and 60 min intravenous glucose tolerance test (IVGTT) were performed at baseline and after 6 months. The subjects were followed up for another 12 months after discontinuation of treatment and a repeat OGTT was performed at 18 months. RESULTS: Thirty-three subjects fulfilled the study. Markers of insulin sensitivity - i.e. fasting insulin and HOMA(IR)-index - improved in the glipizide group (P = 0.04 and 0.02 respectively) as well as HDL cholesterol (P = 0.05) compared with placebo group after 6 months. At 18 months, both fasting and 2 h glucose concentrations were significantly lower in the glipizide group compared with the placebo group (P = 0.04 and 0.03 respectively). The prevalence of type 2 diabetes was 29.4% in the placebo group and 5.9% in the glipizide group at 18 months. This equals an 80% relative risk reduction in the active treatment group. CONCLUSIONS: Short-term treatment with glipizide improves glucose and insulin metabolism in subjects with IGT primarily by improving insulin sensitivity mediated by lowering glucose toxicity, thereby providing the beta cells rest. Larger studies are needed to establish whether these effects are sufficient to prevent progression to manifest type 2 diabetes and associated cardiovascular morbidity in subjects at increased risk of developing type 2 diabetes.     

Correlations of visceral fat accumulation and atherosclerosis in Japanese patients with type 2 diabetes mellitus

We tested the hypothesis that increased abdominal visceral fat accumulation (VFA) is associated with insulin resistance and aortic stiffness in patients with type 2 diabetes mellitus not receiving insulin treatment. The study consisted of 22 Japanese patients with type 2 diabetes mellitus and high VFA (> or =100 cm(2); age, 61 +/- 7 years; high VFA group) and a control group of 18 age-matched patients with normal VFA (<100 cm(2); age, 60 +/- 8 years; normal VFA group). Brachial-ankle pulse wave velocity (BaPWV) was measured by automatic oscillometric method. The BaPWV was used as an index of atherosclerosis. The body mass index values (P < .05), waist circumferences (P < .0005), and waist-to-hip ratios (P < .05) were larger in the high VFA group than in the normal VFA group. The BaPWV was higher in the high VFA group than in the normal VFA group (P < .0001). Fasting plasma glucose (P < .05), insulin concentrations (P < .0001), and the homeostasis model assessment (HOMA) index (P < .001) were higher in the high VFA group than in the normal VFA group. Multiple regression analysis showed that the VFA level was independently predicted by BaPWV and the HOMA index. Our results indicate that the elevation of VFA in Japanese patients with type 2 diabetes mellitus is characterized by increased aortic stiffness and insulin resistance and that BaPWV and the HOMA index are independent predictors of VFA.     

基于卒中登记的进展性缺血性卒中危险因素的前瞻性研究

目的 探讨基于卒中登记的进展性缺血性卒中的危险因素.方法 连续选择2012年1-7月徐州医学院第二附属医院神经内科收治的发病3 d内的缺血性卒中患者221例,其中进展性缺血性卒中32例（进展组）,非进展性缺血性卒中189例（非进展组）.运用卒中注册软件,连续登记缺血性卒中患者的临床资料,对可能引起缺血性卒中进展的危险因素进行单因素分析和二分类Logistic回归分析.结果 进展组患者糖尿病发生率、低密度脂蛋白水平及颅内大血管狭窄发生率高于非进展组（P＜0.05）,高密度脂蛋白水平低于非进展组（P＜0.05）.二分类Logistic回归分析结果显示,糖尿病、高密度脂蛋白降低、颅内大血管狭窄是进展性缺血性卒中的危险因素（OR值分别为2.686、3.339、10.777,P＜0.05）.结论 伴有糖尿病、高密度脂蛋白降低、颅内大动脉狭窄的卒中患者容易发展为进展性,应早期对其进行干预.